Rheumatology

Luebker S, Frech TM, Assassi S, Skaug B, Gordon JK, Lakin K, Bernstein EJ, Luo Y, Steen VD, Shah AA, Hummers LK, Richardson C, Moore[...]

P Singh R, S Bischoff D, S Singh S, H Hahn B. Peptide-based immunotherapy in lupus: Where are we now? Rheumatol Immunol Res. 2023 Sep[...]

La Cava A. Low-dose interleukin-2 therapy in systemic lupus erythematosus. Rheumatol Immunol Res. 2023 Sep 27;4(3):150-156. doi: 10.2478/rir-2023-0021. PMID: 37781677; PMCID: PMC10538619.

Campochiaro C, Suliman YA, Hughes M, Schoones JW, Giuggioli D, Moinzadeh P, Baron M, Chung L, Ross L, Maltez N, Allanore Y, Denton CP, Distler[...]

Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, Gardner GC, Highland KB, Hudson[...]

Bruni C, Buch MH, Djokovic A, De Luca G, Dumitru RB, Giollo A, Galetti I, Steelandt A, Bratis K, Suliman YA, Milinkovic I, Baritussio A,[...]

Last Wednesday, we had the opportunity to celebrate accomplishments of physician scientists, culminating in an event that celebrated the 30th anniversary of the STAR Program at[...]

Kermani TA. Correspondence on 'Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694[...]

Razmjou AA, Wang JM, Shahbazian A, Reddy S, Charles-Schoeman C. Correction to: Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways[...]

Volkmann ER, Sparks JA, Hoffmann-Vold AM, Doyle TJ, Emery P, Dieudé P. Preclinical/subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences. Lancet[...]